Directorate Change
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and SALT LAKE CITY - December 8, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that Dr Chirag Parikh has stepped down from his role as independent Non-Executive Director of Renalytix with immediate effect.
The Company will seek to recruit a new independent Non-Executive Director and will provide an update in due course.
The Ordinary Resolution to re-appoint Dr Parikh to the Board of Directors will be withdrawn for the Annual General Meeting to be held on 15 December 2023.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.